Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXueli JiaoQZQinglan ZhangXLXingchen Liu

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates high efficacy and safety of zanubrutinib in elderly and younger high-risk mantle cell lymphoma patients, indicating potential as a first-line treatment.

Key Points

  • This study aims to evaluate the efficacy and safety of zanubrutinib-containing regimens in newly diagnosed mantle cell lymphoma patients.
  • Multicenter, investigator-initiated, prospective study
  • Cohorts stratified by age and biological risk: elderly (≥65 years) and younger high-risk (<65 years)
  • Patients received zanubrutinib combined with rituximab or R-BAC regimen for induction therapy followed by maintenance.
  • Elderly cohort had an overall response rate (ORR) of 100% and a complete remission (CR) rate of 88.9%
  • Younger high-risk cohort had an ORR of 100% and a CR rate of 84.6%
  • High rates of minimal residual disease negativity were observed, with 80% in the elderly cohort and 87.5% in the younger cohort
  • No grade 3-4 adverse events in elderly cohort; younger cohort reported manageable adverse events.

Cite This Study

Jiao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d478https://doi.org/10.1182/blood-2025-1823
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis2025
  2. 2Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis2026
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.2024 · 2 citations
  5. 5Zanubrutinib maintenance post-autologous stem cell transplantation in Mantle Cell Lymphoma: A prospective multicenter Phase II trial2025